Literature DB >> 20061936

Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.

Theodorus H Van der Kwast1, Andrew Evans, Gina Lockwood, Doug Tkachuk, David G Bostwick, Jonathan I Epstein, Peter A Humphrey, Rodolfo Montironi, Geert J L H Van Leenders, Carl-Gustaf Pihl, Ingrid Neetens, Paula M Kujala, Marita Laurila, Catharine Mazerolles, Lukas Bubendorf, Antonio Finelli, Kemp Watson, John Srigley.   

Abstract

Pathologists are increasingly exposed to prostate biopsies with small atypical foci, requiring differentiation between adenocarcinoma, atypical small acinar proliferation suspicious for malignancy, and a benign diagnosis. We studied the level of agreement for such atypical foci among experts in urologic pathology and all-round reference pathologists of the European Randomized Screening study of Prostate Cancer (ERSPC). For this purpose, we retrieved 20 prostate biopsies with small (most <1 mm) atypical foci. Hematoxylin and eosin-stained slides, including 10 immunostained slides were digitalized for virtual microscopy. The lesional area was not marked. Five experts and 7 ERSPC pathologists examined the cases. Multirater kappa statistics was applied to determine agreement and significant differences between experts and ERSPC pathologists. The kappa value of experts (0.39; confidence interval, 0.29-0.49) was significantly higher than that of ERSPC pathologists (0.21; confidence interval, 0.14-0.27). Full (100%) agreement was reached by the 5 experts for 7 of 20 biopsies. Experts and ERSPC pathologists rendered diagnoses ranging from benign to adenocarcinoma on the same biopsy in 5 and 9 biopsies, respectively. Most of these lesions comprised between 2 and 5 atypical glands. The experts diagnosed adenocarcinoma (49%) more often than the ERSPC pathologists (32%) (P<0.001). As agreement was particularly poor for foci comprising <6 glands, we would encourage pathologists to obtain intercollegial consultation of a specialized pathologist for these lesions before a carcinoma diagnosis, whereas clinicians may consider to perform staging biopsies before engaging on deferred or definite therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061936     DOI: 10.1097/PAS.0b013e3181c7997b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  [Importance of second opinions on histology of prostate biopsy specimens].

Authors:  B Helpap; U Oehler
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

2.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534

3.  Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  T Van der Kwast; L Bubendorf; C Mazerolles; M R Raspollini; G J Van Leenders; C-G Pihl; P Kujala
Journal:  Virchows Arch       Date:  2013-08-06       Impact factor: 4.064

4.  Verification and Validation of Digital Pathology (Whole Slide Imaging) for Primary Histopathological Diagnosis: All Wales Experience.

Authors:  M Babawale; A Gunavardhan; J Walker; T Corfield; P Huey; A Savage; A Bansal; M Atkinson; H Abdelsalam; E Raweily; A Christian; I Evangelou; D Thomas; J Shannon; E Youd; P Brumwell; J Harrison; I Thompson; M Rashid; G Leopold; A Finall; S Roberts; D Housa; P Nedeva; A Davies; D Fletcher; Muhammad Aslam
Journal:  J Pathol Inform       Date:  2021-01-23

5.  Label-free high-resolution imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy.

Authors:  Liang Gao; Haijun Zhou; Michael J Thrall; Fuhai Li; Yaliang Yang; Zhiyong Wang; Pengfei Luo; Kelvin K Wong; Ganesh S Palapattu; Stephen T C Wong
Journal:  Biomed Opt Express       Date:  2011-03-18       Impact factor: 3.732

6.  p40 as a Basal Cell Marker in the Diagnosis of Prostate Glandular Proliferations: A Comparative Immunohistochemical Study with 34betaE12.

Authors:  Hermann Brustmann
Journal:  Patholog Res Int       Date:  2015-03-08

7.  The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.

Authors:  Przemyslaw Waliszewski
Journal:  Front Physiol       Date:  2016-02-11       Impact factor: 4.566

8.  Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology: A Multicenter Blinded Randomized Noninferiority Study of 1992 Cases (Pivotal Study).

Authors:  Sanjay Mukhopadhyay; Michael D Feldman; Esther Abels; Raheela Ashfaq; Senda Beltaifa; Nicolas G Cacciabeve; Helen P Cathro; Liang Cheng; Kumarasen Cooper; Glenn E Dickey; Ryan M Gill; Robert P Heaton; René Kerstens; Guy M Lindberg; Reenu K Malhotra; James W Mandell; Ellen D Manlucu; Anne M Mills; Stacey E Mills; Christopher A Moskaluk; Mischa Nelis; Deepa T Patil; Christopher G Przybycin; Jordan P Reynolds; Brian P Rubin; Mohammad H Saboorian; Mauricio Salicru; Mark A Samols; Charles D Sturgis; Kevin O Turner; Mark R Wick; Ji Y Yoon; Po Zhao; Clive R Taylor
Journal:  Am J Surg Pathol       Date:  2018-01       Impact factor: 6.394

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.